MarketCap
Facebook
X
Telegram
Apellis Pharmaceuticals Cash Conversion Cycle | APLS
Annual Cash Conversion Cycle Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 | 110 | 98.5 | 43.1 | 27.7 | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 115 | 27.7 | 78.8 |
Quarterly Cash Conversion Cycle Apellis Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 115 | 137 | - | 135 | 131 | 126 | - | 116 | 68.4 | 39.9 | - | 32.3 | 38.7 | 52.1 | - | 34.2 | 52.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 137 | 32.3 | 82.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Sangamo Therapeutics
SGMO
|
4.14 | - | - | $ 50.4 M |  USA |
 |
Salarius Pharmaceuticals
SLRX
|
382 | - | - | $ 2.64 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
-545 | - | - | $ 826 K | USA |
 |
Vaxart
VXRT
|
-5.69 | - | -25.06 % | $ 46.3 M | USA |
 |
XOMA Corporation
XOMA
|
23.6 | - | - | $ 485 M | USA |
 |
Sesen Bio
SESN
|
391 | - | 7.29 % | $ 127 M | USA |
 |
Windtree Therapeutics
WINT
|
-145 | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
25.5 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-36.8 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
6.22 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-4.37 K | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B |  Niderland |
 |
Alnylam Pharmaceuticals
ALNY
|
31.7 | $ 156.5 | -2.85 % | $ 20.5 B | USA |
 |
Amgen
AMGN
|
217 | $ 462.71 | -3.3 % | $ 249 B | USA |
 |
Theratechnologies
THTX
|
178 | - | - | $ 83.9 M |  Canada |
 |
Iovance Biotherapeutics
IOVA
|
162 | $ 7.72 | -11.26 % | $ 2.76 M | USA |
 |
Biogen
BIIB
|
337 | $ 243.85 | -4.17 % | $ 35.7 B | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
492 | $ 4.03 | 6.9 % | $ 652 M | USA |
 |
MannKind Corporation
MNKD
|
349 | $ 3.77 | -4.07 % | $ 1.15 B | USA |
 |
Insmed Incorporated
INSM
|
173 | $ 108.79 | -1.1 % | $ 21.7 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
66.2 | $ 227.25 | -3.16 % | $ 13.9 B |  Irlanda |
 |
Bristol-Myers Squibb Company
BMY
|
58.6 | $ 63.15 | -1.64 % | $ 128 B | USA |
 |
Johnson & Johnson
JNJ
|
88.2 | $ 272.47 | -1.4 % | $ 656 B | USA |
 |
Kala Pharmaceuticals
KALA
|
729 | $ 0.15 | -13.14 % | $ 1.22 M | USA |